

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/627,413	07/25/2003	Arthur M. Krieg	C1039.70079US00 3204	
7:	590 06/01/2006	06/01/2006 EXAMINER		INER
Helen C. Lockhart			LE, EMILY M	
Wolf, Greenfield & Sacks, P.C. Federal Reserve Plaza			ART UNIT	PAPER NUMBER
600 Atlantic Avenue Boston, MA 02210			1648	
			DATE MAILED: 06/01/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	,					
	Application No.	Applicant(s)				
	10/627,413	KRIEG ET AL.				
Office Action Summary	Examiner	Art Unit				
	Emily Le	1648				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailine earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 25 J	<u>luly 2003</u> .					
2a) This action is FINAL . 2b) ⊠ This	This action is FINAL . 2b)⊠ This action is non-final.					
) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>42-71</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) ☐ Claim(s) is/are rejected.	•					
7) Claim(s) is/are objected to.						
8) Claim(s) <u>42-71</u> are subject to restriction and/o	or election requirement.					
Application Papers						
9) The specification is objected to by the Examine	er.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of:	n priority under 35 U.S.C. § 119(a)-(d) or (f).				
1. Certified copies of the priority documen	•					
2. Certified copies of the priority documen	• •					
3. Copies of the certified copies of the price		ed in this National Stage				
application from the International Burea * See the attached detailed Office action for a lis		ed.				
See the attached detailed Office action for a lis	t of the certified copies not receive	su.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail D					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date 		ate Patent Application (PTO-152)				

Application/Control Number: 10/627,413 Page 2

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

- 1. This application contains claims directed to the following patentably distinct species: A) 5'TCG-3'; B) 5'-purine, purine, C,G, pyrimidine, pyrimidine, C,C-3'; and C) 5'-purine, purine, C,G, pyrimidine, pyrimidine, C,G-3'.
- 2. Currently, independent claims 42, 50, 57, 64 and 68 are generic to species listed in A), B) and C).
- 3. If Applicant elects item B), Applicant is required to elect one of the following subspecies: a) 5'-GACGTTCC-3'; and b) SEQ ID NO: 3, wherein the sequence has 5'-AACGTTCC-3' motif.
- 4. Claims 44, 52, 59, 65 and 69 are generic to species a) and b).
- 5. If Applicant elects item b), Applicant is further required to elect one of the following sub-species: SEQ ID NOs: 7, 9-10, 35 and 54.
- 6. Claims 45, 53 and 60 are generic to the following species: SEQ ID NO: 7, 9-10, 35 and 54.
- 7. The species are independent or distinct because each of the listed species is not unified by a common utility. In the instant, each has a distinct Th-1 associated cytokine secretory profile. For example, SEQ ID NO: 3 induces IL-6, TNF-alpha, IFN-gamma, GM-CSF, and IL-12 secretion; and SEQ IDNO: 54 induces stimulation of B cell proliferation and IL-12.
- 8. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Art Unit: 1648

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

- 9. The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.
- 10. Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.
- 11. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Le whose telephone number is (571) 272 0903. The examiner can normally be reached on Monday Friday, 8 am 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce R. Campell can be reached on (571) 272-0974. The fax phone

Application/Control Number: 10/627,413

Art Unit: 1648

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Emily tbe ς∖(۲l0
Patent Examiner
Art Unit 1648

Page 4